Free Newsletter
Painkillers little help against dementia
Hopes that painkillers might help stave off Alzheimer's disease were dampened by a large new study. Pfizer's Celebrex and the over-the-counter Aleve didn't benefit thinking skills as researchers had hypothesized. "These were not the results we were hoping for," one of the co-authors said. "We designed this study hoping we would see a protective effect of these drugs." They'll continue monitoring the participants to see if a delayed benefit crops up.
Previous studies had shown that people who took the drugs ran a lower risk of developing Alzheimer's, but those studies weren't designed specifically for that purpose. It's a bummer for Pfizer and Bayer (which makes Aleve), because proof of Alzheimer's prevention would translate into a big new use for those meds. "Unfortunately, as this paper demonstrates, research doesn't always translate into successful new treatments," a philosophical Dr. Gail Cawkwell of Pfizer told the LA Times.
- read the Times article
Related Article:
Big pharma sees big payback for Alzheimer's research
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: